Indisputable: Humira, Biologics Dominate Pharma Sales In 2017
Executive Summary
Demand for the top-selling drug, Humira, continues to break all sales records, leading a charge in which, for the first time, a majority of the top 30 selling drugs were biologics. But 2017 also saw one multiple blockbuster drug lose over 75% of it's sales for reasons other than loss of exclusivity or market withdrawal.
You may also be interested in...
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.